Pancreatic cancer and immune checkpoint inhibitors-still a long way to go.
作者信息
Bian Jessica, Almhanna Khaldoun
机构信息
Division of Hematology/Medical Oncology, Maine Medical Center, MaineHealth Cancer Care, Portland, ME, USA.
Division of Hematology/Oncology, The Warren Alpert Medical School of Brown University, Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, USA.
出版信息
Transl Gastroenterol Hepatol. 2021 Jan 5;6:6. doi: 10.21037/tgh.2020.04.03. eCollection 2021.
Abstract
摘要
相似文献
1
Pancreatic cancer and immune checkpoint inhibitors-still a long way to go.胰腺癌与免疫检查点抑制剂——仍有很长的路要走。
Transl Gastroenterol Hepatol. 2021 Jan 5;6:6. doi: 10.21037/tgh.2020.04.03. eCollection 2021.
2
Immune checkpoint inhibitors in esophagogastric cancer: still a long way to go.免疫检查点抑制剂在食管癌和胃癌中的应用：仍有很长的路要走。
J Thorac Dis. 2019 Feb;11(2):351-353. doi: 10.21037/jtd.2018.11.111.
3
Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.免疫疗法治疗内分泌恶性肿瘤：免疫检查点抑制剂引领潮流。
Endocr Relat Cancer. 2017 Dec;24(12):T261-T281. doi: 10.1530/ERC-17-0222. Epub 2017 Sep 11.
4
Immune checkpoint therapy for pancreatic cancer.胰腺癌的免疫检查点疗法。
World J Gastroenterol. 2016 Nov 21;22(43):9457-9476. doi: 10.3748/wjg.v22.i43.9457.
5
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.胰腺癌中免疫检查点抑制剂的联合全身治疗：克服对单药检查点阻断的耐药性
Clin Transl Med. 2018 Oct 8;7(1):32. doi: 10.1186/s40169-018-0210-9.
6
Checkpoint inhibitors in pancreatic cancer.胰腺癌的检查点抑制剂。
Cancer Treat Rev. 2019 Aug;78:17-30. doi: 10.1016/j.ctrv.2019.06.005. Epub 2019 Jun 27.
7
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.非小细胞肺癌免疫检查点抑制剂的作用机制及潜在预测生物标志物。
Biomed Pharmacother. 2020 Jul;127:109996. doi: 10.1016/j.biopha.2020.109996. Epub 2020 May 6.
8
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.克服 T 细胞耗竭：胰腺癌免疫治疗的新进展。
Cancer Lett. 2016 Oct 10;381(1):259-68. doi: 10.1016/j.canlet.2016.02.057. Epub 2016 Mar 8.
9
The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application.基于癌症免疫检查点疗法的突破：免疫检查点研究进展及其应用综述
Comb Chem High Throughput Screen. 2017;20(5):430-439. doi: 10.2174/1386207320666170315121728.
10
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.
引用本文的文献
1
Single-cell transcriptional dissection illuminates an evolution of immunosuppressive microenvironment during pancreatic ductal adenocarcinoma metastasis.单细胞转录剖析揭示了胰腺导管腺癌转移过程中免疫抑制微环境的演变。
Signal Transduct Target Ther. 2025 Jun 9;10(1):182. doi: 10.1038/s41392-025-02265-0.
2
Interview with the World Class Authorities Frontiers of Cancer Research: An exclusive interview with Professor Luis Diaz.癌症研究前沿：对世界级权威人士的访谈——对路易斯·迪亚兹教授的独家访谈
Ann Gastroenterol Surg. 2025 Mar 3;9(3):401-407. doi: 10.1002/ags3.70003. eCollection 2025 May.
3
Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice.表达抗前列腺干细胞抗原嵌合抗原受体（CAR）和白细胞介素-15的现成不变自然杀伤T细胞可促进小鼠胰腺癌消退。
J Clin Invest. 2025 Apr 15;135(8). doi: 10.1172/JCI179014.
4
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.TIMEPOINT，一项将MTL-CEBPA与帕博利珠单抗联合使用的1期研究，支持MTL-CEBPA在实体瘤中的免疫调节作用。
Cell Rep Med. 2025 Apr 15;6(4):102041. doi: 10.1016/j.xcrm.2025.102041. Epub 2025 Mar 31.
5
Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy.Claudin 18（43-14A克隆体）在胰腺导管腺癌中的表达：评估zolbetuximab治疗的潜在临床生物标志物
Transl Oncol. 2025 May;55:102362. doi: 10.1016/j.tranon.2025.102362. Epub 2025 Mar 20.
6
Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model.丙酰辅酶A羧化酶亚基B在胰腺癌小鼠模型中调节抗肿瘤T细胞。
Elife. 2025 Mar 11;13:RP96925. doi: 10.7554/eLife.96925.
7
Photodynamic priming with red light triggers adaptive immune responses in a pancreatic cancer mouse model.在胰腺癌小鼠模型中，红光光动力预激发可触发适应性免疫反应。
J Photochem Photobiol B. 2025 Apr;265:113126. doi: 10.1016/j.jphotobiol.2025.113126. Epub 2025 Feb 19.
8
The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives.肿瘤微环境在胰腺癌免疫治疗中的作用：现状与未来展望。
Int J Mol Sci. 2024 Sep 3;25(17):9555. doi: 10.3390/ijms25179555.
9
Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS-mutant Cancers.解析 CDK9/PP2A/ERK 网络在 KRAS 突变型癌症中转录暂停释放和补体激活中的作用。
Adv Sci (Weinh). 2024 Nov;11(41):e2404926. doi: 10.1002/advs.202404926. Epub 2024 Sep 10.
10
TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer.TSG-6+ 肿瘤相关成纤维细胞调节髓样细胞反应，并削弱胰腺癌对免疫检查点治疗的抗肿瘤反应。
Nat Commun. 2024 Jul 10;15(1):5291. doi: 10.1038/s41467-024-49189-x.
本文引用的文献
1
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效：来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
2
Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.克服免疫抵抗增强新型抗 tMUC1-CAR T 细胞治疗对胰腺导管腺癌的疗效。
Cells. 2019 Sep 11;8(9):1070. doi: 10.3390/cells8091070.
3
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.一项评估抗 CC 趋化因子受体 4 抗体莫格利珠单抗联合纳武利尤单抗治疗晚期或转移性实体瘤患者的 I 期研究。
Clin Cancer Res. 2019 Nov 15;25(22):6614-6622. doi: 10.1158/1078-0432.CCR-19-1090. Epub 2019 Aug 27.
4
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.度伐利尤单抗联合或不联合曲美木单抗治疗转移性胰腺导管腺癌患者：一项2期随机临床试验
JAMA Oncol. 2019 Oct 1;5(10):1431-1438. doi: 10.1001/jamaoncol.2019.1588.
5
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).一项关于 GVAX 胰腺和 CRS-207 与化疗在先前治疗过的转移性胰腺腺癌成人中的 IIb 期、随机、多中心研究的结果（ECLIPSE 研究）。
Clin Cancer Res. 2019 Sep 15;25(18):5493-5502. doi: 10.1158/1078-0432.CCR-18-2992. Epub 2019 May 24.
6
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗微卫星高度不稳定实体瘤。
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. doi: 10.1158/1078-0432.CCR-18-4070. Epub 2019 Feb 20.
7
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.拓宽免疫疗法在胰腺癌中的应用：挑战与机遇。
Gastroenterology. 2019 May;156(7):2056-2072. doi: 10.1053/j.gastro.2018.12.038. Epub 2019 Jan 18.
8
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.评估胰腺腺癌中错配修复缺陷：挑战与建议。
Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.
9
Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.胰腺导管内乳头状黏液性肿瘤中微卫星不稳定性的发生率。
Gastroenterology. 2018 Mar;154(4):1061-1065. doi: 10.1053/j.gastro.2017.11.009. Epub 2017 Nov 20.
10
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
Zotero 插件